Patents by Inventor Huaixue MU

Huaixue MU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Palladium/silver co-catalyzed tandem reactions synthesis of phenylacetophenone derivatives by oxabenzonorbornadienes with terminal alkynes and their anti-tumor or anti-cancer activities
    Patent number: 9783519
    Abstract: This invention relates to the quick and efficient synthesis of anti-tumor or anti-cancer compounds. More particularly, it relates to the quick and efficient synthesis of anti-tumor or anti-cancer compounds comprising phenylacetophenone derivatives using oxabenzonorbornadienes with terminal alkynes.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: October 10, 2017
    Assignees: HONG KONG BAPTIST UNIVERSITY, YUNNAN MINZU UNIVERSITY
    Inventors: Zhaoxiang Bian, Chengyuan Lin, Huaixue Mu, Baomin Fan, Yongyun Zhou, Jingchao Chen, Aiping Lu, Albert Sun-Chi Chan
  • Lignans isolated from (L.) Thwait
    Patent number: 9775857
    Abstract: The present invention relates to chemical constituents of the hydro-alcoholic extract of root of Lasia spinosa (L.) Thwait. More particularly, it relates to the bioactive chemical composition of Lasia spinosa (L.) Thwait and its anticancer effect. The present invention has application in the treatment of human esophageal carcinoma.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: October 3, 2017
    Assignee: HONG KONG BAPTIST UNIVERSITY
    Inventors: Zhaoxiang Bian, Huaixue Mu, Chengyuan Lin, Hongxi Xu, Dajian Yang, Shilin Chen, Aiping Lu, Albert Sun Chi Chan
  • Anti-esophageal cancer compound and method of use thereof
    Patent number: 9655913
    Abstract: The present invention relates to the bioactive components with the anti-proliferative property. In particular, the invention relates to one flavonol compound isolated from the root of Lasia spinosa Linn. Thwait or chemically synthesized and its specific anticancer/antitumor activity. This invention has a specific application in treating human esophageal cancer.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: May 23, 2017
    Assignees: Hong Kong Baptist University, Changshu HKBU Technology Company Limited
    Inventors: Zhaoxiang Bian, Huaixue Mu, Chengyuan Lin, Jinjin Wang, Zhijun Yang, Aiping Lu, Albert Sun Chi Chan
  • ANTI- ESOPHAGEAL CANCER COMPOUND AND METHOD OF USE THEREOF
    Publication number: 20170014438
    Abstract: The present invention relates to the bioactive components with the anti-proliferative property. In particular, the invention relates to one flavonol compound isolated from the root of Lasia spinosa Linn. Thwait or chemically synthesized and its specific anticancer/antitumor activity. This invention has a specific application in treating human esophageal cancer.
    Type: Application
    Filed: June 23, 2016
    Publication date: January 19, 2017
    Applicants: Changshu HKBU Technology Company Limited
    Inventors: Zhaoxiang Bian, Huaixue Mu, Chengyuan Lin, Jinjin Wang, Zhijun Yang, Aiping Lu, Albert Sun Chi Chan
  • Lignans Isolated from Lasia spinosa (L.) Thwait
    Publication number: 20160375082
    Abstract: The present invention relates to chemical constituents of the hydro-alcoholic extract of root of Lasia spinosa (L.) Thwait. More particularly, it relates to the bioactive chemical composition of Lasia spinosa (L.) Thwait and its anticancer effect. The present invention has application in the treatment of human esophageal carcinoma.
    Type: Application
    Filed: June 23, 2016
    Publication date: December 29, 2016
    Inventors: Zhaoxiang Bian, Huaixue Mu, Chengyuan Lin, Hongxi Xu, Dajian Yang, Shilin Chen, Aiping Lu, Albert Sun Chi Chan
  • Bioactivity proanthocyanidin compound isolated from Lasia spinosa (L.) Thwait
    Publication number: 20160374985
    Abstract: The present invention disclosed a compound, proanthocyanidin A1 (PA1), which is isolated from Lasia spinosa (L.) Thwait, for its effects in shortening of clolon length, reducing colonic tissue damage, suppressing colonic myeloperoxidase activity with colitis. The said compound can be used in treating inflammatory diseases and anti-cancer leading compound.
    Type: Application
    Filed: June 23, 2016
    Publication date: December 29, 2016
    Inventors: Zhaoxiang Bian, Huaixue Mu, Chengyuan Lin, Hongxi Xu, Dajian Yang, Shilin Chen, Aiping Lu, Albert Sun Chi Chan
  • PALLADIUM/SILVER CO-CATALYZED TANDEM REACTIONS SYNTHESIS OF PHENYLACETOPHENONE DERIVATIVES BY OXABENZONORBORNADIENES WITH TERMINAL ALKYNES AND THEIR ANTI-TUMOR OR ANTI-CANCER ACTIVITIES
    Publication number: 20160368890
    Abstract: This invention relates to the quick and efficient synthesis of anti-tumor or anti-cancer compounds.
    Type: Application
    Filed: June 18, 2015
    Publication date: December 22, 2016
    Inventors: Zhaoxiang BIAN, Chengyuan LIN, Huaixue MU, Baomin FAN, Yongyun ZHOU, Jingchao CHEN, Aiping LU, Albert Sun-Chi CHAN
  • (+)-3?-angeloyloxy-4?-keto-3?,4?-dihydroseselin for treating inflammation
    Patent number: 9408828
    Abstract: The present invention provides a compound, namely (+)-3?-Angeloyloxy-4?-keto-3?,4?-dihydroseselin (Pd-Ib) derived from Bupleurum malconense as the potential anti-inflammation drug. The present invention also relates to methods of preparing the compounds and using the same for treating inflammation.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: August 9, 2016
    Inventors: Zhaoxiang Bian, Huaixue Mu, Chengyuan Lin, Quanbin Han, Aiping Lu, Linfang Huang, Shilin Chen, Dajian Yang, Hongxi Xu, Sun Chi Albert Chan
  • Pd-Ib for Treating Inflammation
    Publication number: 20150366841
    Abstract: The present invention provides a compound, namely (+)-3?-Angeloyloxy-4?-keto-3?, 4?-dihydroseselin (Pd-Ib) derived from Bupleurum malconense as the potential anti-inflammation drug. The present invention also relates to methods of preparing the compounds and using the same for treating inflammation.
    Type: Application
    Filed: June 18, 2015
    Publication date: December 24, 2015
    Inventors: Zhaoxiang BIAN, Huaixue MU, Chengyuan LIN, Quanbin HAN, Aiping LU, Linfang HUANG, Shilin CHEN, Dajian YANG, Hongxi XU, Sun Chi Albert CHAN
  • Oxanorbornadiene derivatives and their anticancer activities
    Patent number: 9120816
    Abstract: The present invention relates to chemical entities originated from natural sources and further synthesized for therapeutic uses. More particularly, the present invention relates to norcantharidin analogs synthesized by a transition metal-catalyzed alkynylation of oxanorbornadiene derivatives and their antitumor effects.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: September 1, 2015
    Assignee: HONG KONG BAPTIST UNIVERSITY
    Inventors: Zhaoxiang Bian, Chengyuan Lin, Baomin Fan, Huaixue Mu, Yongyun Zhou, Weimin Zeng, Aiping Lu, Albert Sun Chi Chan
  • OXANORBORNADIENE DERIVATIVES AND THEIR ANTICANCER ACTIVITIES
    Publication number: 20140187626
    Abstract: The present invention relates to chemical entities originated from natural sources and further synthesized for therapeutic uses. More particularly, the present invention relates to norcantharidin analogues synthesized by a transition metal-catalyzed alkynylation of oxanorbornadiene derivatives and their antitumor effects.
    Type: Application
    Filed: December 16, 2013
    Publication date: July 3, 2014
    Applicant: Hong Kong Baptist University
    Inventors: Zhaoxiang BIAN, Chengyuan LIN, Baomin FAN, Huaixue MU, Yongyun ZHOU, Weimin ZENG, Aiping LU, Albert Sun Chi CHAN